---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-25-000068"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T17:03:42.969758+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Castle Q1 revenue $88M (+21% YoY), raises FY guidance to $287-297M, acquires Previse

## Summary
- Q1 revenue $88.0M (+21% YoY); total test reports 24,402 (+17%); core driver reports +33% YoY.
- Net loss $(0.90) per share incl. $20.1M amortization acceleration; adjusted net loss $(0.20); Adj. EBITDA $13.0M.
- FY 2025 revenue guidance raised to $287-297M from prior $280-295M.
- Signed definitive agreement to acquire Previse, a GI health company focused on esophageal cancer; no terms disclosed.
- DecisionDx-Melanoma surpassed 200,000 test orders; IDgenetix test to be discontinued effective May 2025.

## SEC filing metadata
- accession: 0001447362-25-000068
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736225000068/0001447362-25-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736225000068/cstl-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-25-000068
- JSON: https://secwatch.observer/filing/0001447362-25-000068.json
- Plain text: https://secwatch.observer/filing/0001447362-25-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.